Log in

Paradigm Biopharmaceuticals Limited (PAR.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: A$2.41
52-Week Range N/A
Volume1.81 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 9629 5566



Sales & Book Value

Annual Sales$3.65 million
Book ValueA$0.48 per share



Next Earnings DateN/A

Receive PAR News and Ratings via Email

Sign-up to receive the latest news and ratings for PAR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Paradigm Biopharmaceuticals Limited (PAR.AX) (ASX:PAR) Frequently Asked Questions

What stocks does MarketBeat like better than Paradigm Biopharmaceuticals Limited (PAR.AX)?

Wall Street analysts have given Paradigm Biopharmaceuticals Limited (PAR.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Paradigm Biopharmaceuticals Limited (PAR.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Paradigm Biopharmaceuticals Limited (PAR.AX)'s key competitors?

What other stocks do shareholders of Paradigm Biopharmaceuticals Limited (PAR.AX) own?

Who are Paradigm Biopharmaceuticals Limited (PAR.AX)'s key executives?

Paradigm Biopharmaceuticals Limited (PAR.AX)'s management team includes the following people:
  • Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC, CEO, MD & Interim Exec. Chairman (Age 61, Pay $632.36k)
  • Mr. Justin Cahill, Chief Financial Officer
  • Dr. Jeannette Joughin, Chief Operating Officer
  • Dr. Ravi Krishnan, Chief Scientific Officer
  • Simon White, Director of Investor Relations
  • Dr. Michael Imperiale, Global Head of Safety
  • Dr. Donna L. Skerrett, Chief Medical Officer & Exec. Director (Age 63)
  • Ms. Beverley Huttmann, Commercial Head
  • Mr. Kevin G. Hollingsworth, Company Sec. (Age 67)

What is Paradigm Biopharmaceuticals Limited (PAR.AX)'s stock symbol?

Paradigm Biopharmaceuticals Limited (PAR.AX) trades on the ASX under the ticker symbol "PAR."

How big of a company is Paradigm Biopharmaceuticals Limited (PAR.AX)?

Paradigm Biopharmaceuticals Limited (PAR.AX) has a market capitalization of $0.00 and generates $3.65 million in revenue each year.

What is Paradigm Biopharmaceuticals Limited (PAR.AX)'s official website?

The official website for Paradigm Biopharmaceuticals Limited (PAR.AX) is www.paradigmbiopharma.com.

How can I contact Paradigm Biopharmaceuticals Limited (PAR.AX)?

The company can be reached via phone at 61 3 9629 5566.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.